Quality of life assessment in Taiwanese patients with bone metastases from breast cancer receiving zoledronic acid

Ta Chung Chao, Dar Ren Chen, Tsu Yi Chao, Shin Cheh Chen, Dah Cherng Yeh, Hwei Chung Wang, Wen Tsung Huang, Kun Ming Rau, King Jen Chang, Tsen Long Yang, Kuan Der Lee, Cheng Jeng Tai, Ling Ming Tseng, Ming Feng Hou

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The current study aimed to examine the impact of zoledronic acid therapy on health-related quality of life (HRQoL) in Taiwanese patients with bone metastases from breast cancer. Patients and Methods: Patients with bone metastases from breast cancer who received zoledronic acid according to the standards of care were enrolled in this observational phase IV study. HRQoL was measured monthly using the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (QLQ-C30) and the breast cancer-specific module (BR-23) for 24 months. Results: A total of 366 patients from 13 centers were enrolled. QLQ C-30 demonstrated that zoledronic acid improved the HRQoL in different aspects. In particular, a significant reduction of pain in the first 14 months and the 22-month follow-up was reported by patients. QLQ-BR23 indicated improved future perspective and breast symptom scores over the course of the study. Conclusion: These data confirm the HRQoL benefits and safety of zoledronic acid in Taiwanese patients with bone metastases from breast cancer.

Original languageEnglish
Pages (from-to)5543-5548
Number of pages6
JournalAnticancer Research
Volume33
Issue number12
Publication statusPublished - Dec 2013

Fingerprint

zoledronic acid
Quality of Life
Breast Neoplasms
Neoplasm Metastasis
Bone and Bones
Standard of Care
Breast
Organizations

Keywords

  • Bone metastases
  • Breast cancer
  • Quality of life
  • Zoledronic acid

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chao, T. C., Chen, D. R., Chao, T. Y., Chen, S. C., Yeh, D. C., Wang, H. C., ... Hou, M. F. (2013). Quality of life assessment in Taiwanese patients with bone metastases from breast cancer receiving zoledronic acid. Anticancer Research, 33(12), 5543-5548.

Quality of life assessment in Taiwanese patients with bone metastases from breast cancer receiving zoledronic acid. / Chao, Ta Chung; Chen, Dar Ren; Chao, Tsu Yi; Chen, Shin Cheh; Yeh, Dah Cherng; Wang, Hwei Chung; Huang, Wen Tsung; Rau, Kun Ming; Chang, King Jen; Yang, Tsen Long; Lee, Kuan Der; Tai, Cheng Jeng; Tseng, Ling Ming; Hou, Ming Feng.

In: Anticancer Research, Vol. 33, No. 12, 12.2013, p. 5543-5548.

Research output: Contribution to journalArticle

Chao, TC, Chen, DR, Chao, TY, Chen, SC, Yeh, DC, Wang, HC, Huang, WT, Rau, KM, Chang, KJ, Yang, TL, Lee, KD, Tai, CJ, Tseng, LM & Hou, MF 2013, 'Quality of life assessment in Taiwanese patients with bone metastases from breast cancer receiving zoledronic acid', Anticancer Research, vol. 33, no. 12, pp. 5543-5548.
Chao, Ta Chung ; Chen, Dar Ren ; Chao, Tsu Yi ; Chen, Shin Cheh ; Yeh, Dah Cherng ; Wang, Hwei Chung ; Huang, Wen Tsung ; Rau, Kun Ming ; Chang, King Jen ; Yang, Tsen Long ; Lee, Kuan Der ; Tai, Cheng Jeng ; Tseng, Ling Ming ; Hou, Ming Feng. / Quality of life assessment in Taiwanese patients with bone metastases from breast cancer receiving zoledronic acid. In: Anticancer Research. 2013 ; Vol. 33, No. 12. pp. 5543-5548.
@article{ecca127991a344e4b06631e591b1c6c3,
title = "Quality of life assessment in Taiwanese patients with bone metastases from breast cancer receiving zoledronic acid",
abstract = "Background: The current study aimed to examine the impact of zoledronic acid therapy on health-related quality of life (HRQoL) in Taiwanese patients with bone metastases from breast cancer. Patients and Methods: Patients with bone metastases from breast cancer who received zoledronic acid according to the standards of care were enrolled in this observational phase IV study. HRQoL was measured monthly using the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (QLQ-C30) and the breast cancer-specific module (BR-23) for 24 months. Results: A total of 366 patients from 13 centers were enrolled. QLQ C-30 demonstrated that zoledronic acid improved the HRQoL in different aspects. In particular, a significant reduction of pain in the first 14 months and the 22-month follow-up was reported by patients. QLQ-BR23 indicated improved future perspective and breast symptom scores over the course of the study. Conclusion: These data confirm the HRQoL benefits and safety of zoledronic acid in Taiwanese patients with bone metastases from breast cancer.",
keywords = "Bone metastases, Breast cancer, Quality of life, Zoledronic acid",
author = "Chao, {Ta Chung} and Chen, {Dar Ren} and Chao, {Tsu Yi} and Chen, {Shin Cheh} and Yeh, {Dah Cherng} and Wang, {Hwei Chung} and Huang, {Wen Tsung} and Rau, {Kun Ming} and Chang, {King Jen} and Yang, {Tsen Long} and Lee, {Kuan Der} and Tai, {Cheng Jeng} and Tseng, {Ling Ming} and Hou, {Ming Feng}",
year = "2013",
month = "12",
language = "English",
volume = "33",
pages = "5543--5548",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "12",

}

TY - JOUR

T1 - Quality of life assessment in Taiwanese patients with bone metastases from breast cancer receiving zoledronic acid

AU - Chao, Ta Chung

AU - Chen, Dar Ren

AU - Chao, Tsu Yi

AU - Chen, Shin Cheh

AU - Yeh, Dah Cherng

AU - Wang, Hwei Chung

AU - Huang, Wen Tsung

AU - Rau, Kun Ming

AU - Chang, King Jen

AU - Yang, Tsen Long

AU - Lee, Kuan Der

AU - Tai, Cheng Jeng

AU - Tseng, Ling Ming

AU - Hou, Ming Feng

PY - 2013/12

Y1 - 2013/12

N2 - Background: The current study aimed to examine the impact of zoledronic acid therapy on health-related quality of life (HRQoL) in Taiwanese patients with bone metastases from breast cancer. Patients and Methods: Patients with bone metastases from breast cancer who received zoledronic acid according to the standards of care were enrolled in this observational phase IV study. HRQoL was measured monthly using the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (QLQ-C30) and the breast cancer-specific module (BR-23) for 24 months. Results: A total of 366 patients from 13 centers were enrolled. QLQ C-30 demonstrated that zoledronic acid improved the HRQoL in different aspects. In particular, a significant reduction of pain in the first 14 months and the 22-month follow-up was reported by patients. QLQ-BR23 indicated improved future perspective and breast symptom scores over the course of the study. Conclusion: These data confirm the HRQoL benefits and safety of zoledronic acid in Taiwanese patients with bone metastases from breast cancer.

AB - Background: The current study aimed to examine the impact of zoledronic acid therapy on health-related quality of life (HRQoL) in Taiwanese patients with bone metastases from breast cancer. Patients and Methods: Patients with bone metastases from breast cancer who received zoledronic acid according to the standards of care were enrolled in this observational phase IV study. HRQoL was measured monthly using the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (QLQ-C30) and the breast cancer-specific module (BR-23) for 24 months. Results: A total of 366 patients from 13 centers were enrolled. QLQ C-30 demonstrated that zoledronic acid improved the HRQoL in different aspects. In particular, a significant reduction of pain in the first 14 months and the 22-month follow-up was reported by patients. QLQ-BR23 indicated improved future perspective and breast symptom scores over the course of the study. Conclusion: These data confirm the HRQoL benefits and safety of zoledronic acid in Taiwanese patients with bone metastases from breast cancer.

KW - Bone metastases

KW - Breast cancer

KW - Quality of life

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=84891391397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891391397&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 5543

EP - 5548

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -